BioCryst Pharmaceuticals, Inc. Earnings Recaps
Q2 2026
Aug 7, 2026
BioCryst’s shares gained 3.1% following Q2 results highlighted by solid ORLADEYO revenue growth and successful pediatric launch execution, reflecting confidence in commercial momentum and operational progress.
Key takeaways
- Total revenue rose 45% year-over-year on a comparable basis, excluding the European divestiture.
- ORLADEYO revenue increased 10% year-over-year to $158.2 million, supported by strong new patient demand and steady new prescriber additions.
- Pediatric ORLADEYO pellets launched with 47 prescriptions received through July 31, exceeding full-year expectations despite earlier manufacturing delays.
- Paid prescription rate improved slightly to 84%, up from 83% a year ago, following completion of a major reauthorization season.
- Strategic shift to end internal drug discovery to focus on external innovation aims to build a more balanced pipeline without impacting current clinical programs.
Q3 2025
Nov 5, 2025
BioCryst reported a robust Q3 2025, driven by strong revenue growth for ORLADEYO, strategic divestitures, and a clean balance sheet, setting the stage for future expansion.
Key takeaways
- ORLADEYO revenue guidance raised to $590-$600 million for 2025, even amid increased competition.
- Successful divestiture of European operations and debt payoff, resulting in an operating profit and positive cash flow.
- Encouraging early data expected from the BCX17725 study for Netherton syndrome, with patient enrollment slightly delayed.
- Anticipating the acquisition of Astria to enhance the pipeline with navenibart, targeting expanded HAE treatment options.
- New prescriptions for ORLADEYO exceeded prior year totals, reflecting continued strong market demand and physician trust.